{
  "docId": "019de070-cb6f-702e-8ba7-38c2ee57750d",
  "docSlug": "70846fe5de6d20355c3868d80f4845b0",
  "documentTitle": "BioNTech | Results Presentation Deck | 36 slides",
  "authorId": "biontech",
  "authorName": "BioNTech",
  "documentKindSlug": "conference-presentation",
  "documentKindLabel": "Conference presentation",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2021-03-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 24,
  "pageCount": 36,
  "prevPage": 23,
  "nextPage": 25,
  "slideType": "propose_solution",
  "function": "present_solution",
  "density": "dense",
  "nDataPoints": 0,
  "notes": "The slide uses a comparison framework to contrast the pharmacokinetic profile of recombinant cytokines (spiky) vs RiboCytokines (sustained).",
  "elementsJson": null,
  "metadataConfidence": 0.95,
  "imagePath": null,
  "slideHref": "/slides/019de070-cb6f-702e-8ba7-38c2ee57750d/24",
  "deckHref": "/decks/019de070-cb6f-702e-8ba7-38c2ee57750d",
  "deckJsonHref": "/decks/019de070-cb6f-702e-8ba7-38c2ee57750d.json",
  "deckAnchorHref": "/decks/019de070-cb6f-702e-8ba7-38c2ee57750d#slide-24",
  "components": [
    {
      "bbox": {
        "h": 0.25,
        "w": 0.35,
        "x": 0.1,
        "y": 0.58
      },
      "kind": "chart",
      "text": "Serum concentration vs Time graph comparing Recombinant Cytokine (spikes) to RiboCytokine (sustained curve).",
      "attrs": null,
      "subkind": "line",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "2a1058a6-10ac-4878-89f1-29cf5d5d5be5",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.12,
        "w": 0.4,
        "x": 0.52,
        "y": 0.28
      },
      "kind": "image",
      "text": "Icons showing T-cell proliferation, T-cell survival (with X), and T-cell effector function.",
      "attrs": null,
      "subkind": "illustration",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "bee80de6-ea5e-43a7-9c1e-cd381c624323",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.6,
        "w": 0.45,
        "x": 0.51,
        "y": 0.2
      },
      "kind": "list",
      "text": "BNT151: Optimized mRNA-encoded IL-2. BNT151 is nucleoside-modified mRNA encoding human IL-2 variant fused to human albumin. IL-2 is a key cytokine in T cell immunity. BNT151 stimulates anti-tumoral T cells. First patient dosed.",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "433255c7-cc5a-4766-8538-fd477e7a49b2",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.35,
        "w": 0.45,
        "x": 0.04,
        "y": 0.2
      },
      "kind": "list",
      "text": "RiboCytokines: A novel therapeutic concept. Cytokines encoded by mRNA and produced in patient. Major improvements: Prolonged serum half-life, High bioavailability, Lower/less frequent dosing, Lower Toxicity, Sequence modifications easy to introduce.",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "e09da34a-1fd1-4efe-80d3-3b822ed1e272",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.03,
        "w": 0.4,
        "x": 0.08,
        "y": 0.95
      },
      "kind": "source-note",
      "text": "Vormehr, M. et al. SITC Poster Sess. (2019); Vormehr, M. et al. CICON Poster Sess. (2019)",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "6717a171-0f18-490a-802f-60921fdbaa67",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.06,
        "w": 0.92,
        "x": 0.04,
        "y": 0.08
      },
      "kind": "title",
      "text": "BNT151: Designed to overcome limitations of recombinant cytokine therapy",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "1ac82bbe-a761-4483-b59f-eae39718162c",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [
    {
      "name": "before-after-framing",
      "slug": null,
      "matchId": "cc4a57ef-8e25-47e7-8e6c-0e7fa81b0dc8",
      "evidence": "Contrasts limitations of recombinant cytokine therapy with the benefits of BNT151.",
      "confidence": 0.9
    }
  ],
  "arcBeats": [],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}